Citations refer to the original publication, not to a Scieee localized version.
Guerra Veloz, M. F., Argüelles Arias, F., Laria, L. C., Maldonado Pérez, B., Benítez Roldán, A., Perea Amarillo, R., Merino Bohórquez, V., Calleja, M. Á., Caunedo Álvarez, Á., & Vilches Arenas, Á. (2018). Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. Baishideng Publishing Group Inc. https://doi.org/10.3748/wjg.v24.i46.5288
Guerra Veloz, María Fernanda, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. Baishideng Publishing Group Inc, 2018. https://doi.org/10.3748/wjg.v24.i46.5288.
Guerra Veloz, María Fernanda, Federico Argüelles Arias, Luisa Castro Laria, Belén Maldonado Pérez, Antonio Benítez Roldán, Raúl Perea Amarillo, Vicente Merino Bohórquez, Miguel Ángel Calleja, Ángel Caunedo Álvarez, and Ángel Vilches Arenas. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. Baishideng Publishing Group Inc, 2018. https://doi.org/10.3748/wjg.v24.i46.5288.
Guerra Veloz, M. F. et al. (2018) Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. Baishideng Publishing Group Inc. Available at: https://doi.org/10.3748/wjg.v24.i46.5288.
M. F. Guerra Veloz et al., “Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease,” Baishideng Publishing Group Inc, 2018, doi: 10.3748/wjg.v24.i46.5288.
@misc{guerraveloz2018loss,
author = {Guerra Veloz, María Fernanda and Argüelles Arias, Federico and Laria, Luisa Castro and Maldonado Pérez, Belén and Benítez Roldán, Antonio and Perea Amarillo, Raúl and Merino Bohórquez, Vicente and Calleja, Miguel Ángel and Caunedo Álvarez, Ángel and Vilches Arenas, Ángel},
title = {Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease},
year = {2018},
publisher = {Baishideng Publishing Group Inc},
doi = {10.3748/wjg.v24.i46.5288},
url = {https://doi.org/10.3748/wjg.v24.i46.5288}
}
The source metadata has no journal, volume or pages. Add them from the original publication if your citation needs them.
